2-Methyl-2-azabicyclo[2.2.1]heptan-5-amine | 93798-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Methyl-2-azabicyclo[2.2.1]heptan-5-amine
• CAS: 93798-22-2
• 化学式: C₇H₁₄N₂
• 分子量: 126.2
• InChiKey: XDRDPPRAPKQIBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 、 2-甲基-2-氮杂双环[2.2.2]-5-辛胺 、 tert-butyl 5-amino-2-azabicyclo[2.2.2]octane-2-carboxylate 、 2-Methyl-2-azabicyclo[2.2.1]heptan-5-amine 、 indolizidin-6-ylamine 以8-Methyl-8-azabicyclo[3.2.1]octan-3-amine was obtained from commercial sources as a variable mixture of endo-的产率得到3-氨基托烷
  参考文献：
  名称：

  Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

  摘要：

  本发明涉及尼古丁乙酰胆碱受体(nACh受体)配体、nACh受体的激活以及与缺陷或故障的尼古丁乙酰胆碱受体，特别是大脑有关的疾病条件的治疗有关的领域。此外，本发明涉及新型化合物(吲唑和苯并噻唑)，其作为α7 nACh受体亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及使用这种化合物的方法。

  公开号：

  US07902217B2

文献信息

• TRICYCLIC GYRASE INHIBITORS
  申请人：Bensen Daniel

  公开号：US20120238751A1

  公开（公告）日：2012-09-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有式I结构的化合物，以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药，相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
• Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
  申请人：Xie Wenge

  公开号：US20050250808A1

  公开（公告）日：2005-11-10

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明一般涉及尼古丁型乙酰胆碱受体（nACh受体）的配体领域，nACh受体的激活，以及与缺陷或功能异常的尼古丁型乙酰胆碱受体相关的疾病状况的治疗，尤其是大脑的治疗。此外，本发明涉及新型化合物（吲唑和苯并噻唑），其作为α7 nACh受体亚型的配体，制备此类化合物的方法，含有此类化合物的组合物，以及使用这些方法。
• INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：Xie Wenge

  公开号：US20090118232A1

  公开（公告）日：2009-05-07

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及乙酰胆碱受体配体(nACh受体)、nACh受体的激活以及与缺陷或失灵的乙酰胆碱受体相关的疾病状态的治疗，特别是大脑的治疗领域。此外，本发明涉及新型化合物(吲唑和苯并噻唑)，这些化合物作为α7 nACh受体亚型的配体，制备这些化合物的方法，含有这些化合物的组合物以及使用这些组合物的方法。
• GYRASE INHIBITORS
  申请人：Creighton Christopher J.

  公开号：US20130079323A1

  公开（公告）日：2013-03-28

  Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR 5 ; R 5 is H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR 7 , or CR 8 R 9 ; R 7 is H or C 1-3 alkyl; R 8 and R 9 are each independently H or C 1-3 alkyl; R 2 is H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; R 4 is H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein R 5 and R 4 together may join to form a fused ring; and R 6 is selected from the group consisting of H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, halo C 1-5 alkyl, halo C 2-5 alkenyl, halo C 2-5 alkynyl, C 1-5 hydroxyalkyl, C 1-5 alkyl chloride, C 2-5 alkenyl chloride, and C 2-5 alkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.

  新型螺旋酶抑制剂及相关组合物和方法，适用于阻碍细菌生长。其中公开了式（I）的化合物：式（I），其中Y为N或CH；Z为N或CR5；R5为H，含有0-2个来自O、S和N的杂原子的取代或未取代的碳氢基残基（1-3C），或为无机残基；L为O、S、NR7或CR8R9；R7为H或C1-3烷基；R8和R9各自独立地为H或C1-3烷基；R2为H，含有0-10个来自O、S和N的杂原子的碳氢基残基（1-40C），可选地取代为无机残基；R4为H、无机残基或含有0-12个来自O、S和N的杂原子和含有0-10个无机残基的碳氢基残基（1-30C），其中R5和R4可以共同形成融合环；R6选自H、C1-5烷基、C2-5烯基、C2-5炔基、卤代C1-5烷基、卤代C2-5烯基、卤代C2-5炔基、C1-5羟基烷基、C1-5氯代烷基、C2-5氯代烯基和C2-5氯代炔基的群；或其药学上可接受的盐、酯或前药。
• Amide derivatives of azabicycloalkanes
  申请人：BEECHAM GROUP PLC

  公开号：EP0115933A2

  公开（公告）日：1984-08-15

  Compounds of formula (I), pharmaceutically acceptable salts, quaternary derivatives and N-oxides thereof, and pharmaceutically acceptable solvates of any of the foregoing: wherein p is 1 to 3; B is C1-7 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-2 alkyl, or a group (CH2)tR11 where t is 1 or 2 and R11 is thienyl or furyl optionally substituted by one or two substituents selected from C1-6 alkyl, C1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolysable acyloxy; and i) A is a group of formula (II): in which either a) one of X and Y is CO and the other is NH; and R, is selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, and amino optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl, phenyl and phenyl C1-4 alkyl groups or optionally N,N-disubstituted by C4-5 polymethylene; or X is CO and Y is NR6 where R1 and R6 together are C1-2 alkylene; and either R2, R3 and R4 are each independently selected from the hydrogen, halogen, CF3, C1-6 alkyl, C1-6 alkoxy, C1-6 thio. C1-7 acyl, C1-7 carboxylic acylamino, C1-6 alkyl- amino, N-(C1-6alkyl-sulphonyl)-N-C1 4 alkylamino, alkylsulphonyl, C1-6 alkylsulphinyl, hydroxy, nitro, or aminocarbonyl, aminosclphonyl, aminosulphonyl- N-(aminosulphonyl)-N-C1-4 alkylamino optionally N-substituted by ore or two groups selected from C1-6 alkyl, C3-8 C8-8 cycloalkyl C1-4 alkyl, phenyl and phenyl C1-4 optionally N,N-disubstituted by C4.5 polymethylene; or one of R2, R3 and R4 is selected from the foregoing class and the remaining two of R2, R3 and R4 when on adjacent atoms are together C1-2 alkylenedioxy; or one of X and Y is CO and the other is NH; R1 and R2 together are C1-2 alkylenedioxy or C1-2 oxyalkylenethio, or C2-3 alkyleneoxy in which the oxygen atom is attached to the ring at the 2- position; as depicted in formula (II); and R3 and R4 are each independently selected from the class of values recited hereinbefore for R2, R3 and R4 in paragraph i) a) fereinbefore or when on adjacent atoms are together C1-2 alkylenedioxy; or iii A is a group of formula (III): in which one of X and Y is CO and the other is NH; and R22, R23 and R24 are each independently selected from the class of values of the variables R2, R3 and R4 as defined hereinbefore in paragraph i) a) in relation to formula (II), except C1-2 alkylenedioxy, having useful pharmacological properties, pharmaceutical compositions containing them, a process and intermediates for their preparation, and the use of the compounds.

  式 (I) 化合物、其药学上可接受的盐、季衍生物和 N-氧化物，以及上述任何物质的药学上可接受的溶液： 其中 p 是 1 至 3； B 是 C1-7 烷基、C3-8 环烷基、C3-8 环烷基 C1-2 烷基或基团 (CH2)tR11，其中 t 是 1 或 2，R11 是噻吩基或呋喃基，任选被选自 C1-6 烷基、C1-6 烷氧基、三氟甲基或卤素的一个或两个取代基取代、或苯基，可任选被一个或两个选自 C1-4 烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和可任选被羟基、C1-4 烷氧基、羧基、酯化羧基或体内可水解酰氧基取代的 C1-4 烷基的取代基取代；和 i) A 是式 (II) 的基团： 其中 a) X 和 Y 中的一个是 CO，另一个是 NH；以及 R，选自卤素、C1-6 烷基、C1-6 烷氧基、C1-6 硫代烷基和氨基，任选被一个或两个选自 C1-6 烷基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基、苯基和苯基 C1-4 烷基的基团取代，或任选被 C4-5 聚亚甲基 N，N-二取代；或 X 是 CO，Y 是 NR6，其中 R1 和 R6 合在一起是 C1-2 亚烷基；以及 R2、R3 和 R4 各自独立地选自氢、卤素、CF3、C1-6 烷基、C1-6 烷氧基、C1-6 硫代C1-7酰基、C1-7羧基酰氨基、C1-6烷基氨基、N-（C1-6烷基-磺酰基）-N-C1 4烷基氨基、烷基磺酰基、C1-6烷基亚磺酰基、羟基、硝基或氨基羰基、氨基磺酰基、氨磺酰-N-(氨磺酰)-N-C1-4 烷基氨基，可选择被选自 C1-6 烷基、C3-8-C8-8 环烷基、C1-4 烷基、苯基和苯基 C1-4 的矿石基或两个基团 N 取代，可选择被 C4.5 聚亚甲基；或 R2、R3 和 R4 中的一个选自前述类别，R2、R3 和 R4 中的其余两个在相邻原子上共同为 C1-2 亚烷基二氧基；或 X 和 Y 中的一个是 CO，另一个是 NH；R1 和 R2 合在一起是 C1-2 亚烷基二氧基或 C1-2 氧代亚烷基硫代或 C2-3 亚烷氧基，其中氧原子在 2- 位连接到环上；如式 (II) 所示；以及 R3 和 R4 各自独立地选自上文第 i)a)段中为 R2、R3 和 R4 所述的数值类别，或当相邻原子上的 C1-2 亚烷基二氧基在一起时；或 iii A 是式(III)的基团： 其中 X 和 Y 中的一个是 CO，另一个是 NH；以及 R22、R23 和 R24 各自独立地选自上文第 i) a)段定义的与式(II)有关的变量 R2、R3 和 R4 的数值类别，但 C1-2 烷二氧基除外。 这些化合物具有有用的药理特性、含有这些化合物的药物组合物、制备这些化合物的工艺和中间体，以及这些化合物的用途。